Holen Sie sich die Stockscreener-App
13.55
0.95%
-0.13
Handel nachbörslich:
13.55
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy - Moomoo
Olema Oncology and Bayer Partner on Clinical Trial to Evaluate OP-3136 and NUBEQA® in Metastatic Castration-Resistant Prostate Cancer 1 - Minichart
Olema Pharmaceuticals (OLMA) Teams Up with Bayer for Clinical Trial - GuruFocus
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer - The Manila Times
Olema oncology announces clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 in combination with Nubeqa® (darolutamide) in metastatic castration-resistant prostate cancer - marketscreener.com
Olema Oncology (NASDAQ: OLMA) inks Bayer trial deal for OP-3136 combo - Stock Titan
New prostate cancer trial pairs Olema drug with Bayer’s NUBEQA - Stock Titan
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap - Yahoo Finance
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Olema Oncology sees early hope as cancer drug shows tumor shrinkage in phase 1 study - MSN
Olema Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:OLMA - Benzinga
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study - Yahoo Finance
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy - Investing.com
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Olema Oncology Reports Promising Phase 1 Results for OP-3136 KAT6 Inhibitor in Advanced Solid Tumors at 2026 ASCO Meeting 12 - Minichart
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting - Sahm
Olema reports phase 1 data for cancer drug OP-3136 By Investing.com - Investing.com South Africa
Olema reports phase 1 data for cancer drug OP-3136 - Investing.com UK
Olema Pharmaceuticals Reports Promising Initial Data for OP-3136 in Phase 1 Study Evaluating KAT6 Inhibitor for Advanced Solid Tumors - Quiver Quantitative
Olema Oncology (NASDAQ: OLMA) shares early OP-3136 Phase 1 cancer data - Stock Titan
Early cancer trial sees tumor shrinkage in 13 of 19 on Olema drug - Stock Titan
Olema Pharmaceuticals (OLMA) Valuation After Encouraging New OP-3136 Phase 1 Data - Sahm
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Olema Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Quiver Quantitative
Breast cancer-focused Olema plans 3 investor talks across May and June - Stock Titan
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $52 - Moomoo
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Olema Pharmaceuticals (OLMA) Deepens Trial Spend With Ample Cash Buffer Is Its Risk-Reward Now Clearer? - Sahm
Olema Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Bain Capital (OLMA) discloses 8.2% position including pre-funded warrant - Stock Titan
Janus Henderson (NASDAQ: OLMA) discloses 7.11M shares, 8.2% stake - Stock Titan
Olema: The Market Overreacted To Roche's SERD Failure - Seeking Alpha
Legal operations leadership role opens as Olema Pharmaceuticals launches search for senior manager - Traders Union
Olema Oncology (OLMA) Gains Attention with Upcoming Clinical Res - GuruFocus
Citi Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $23 to $48 - Moomoo
Goldman Sachs Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
OLMA Maintained by Guggenheim -- Price Target Lowered to $35.00 - GuruFocus
OpenAI pushed this startup out of San Francisco, but it found a brand-new space elsewhere - The Business Journals
Guggenheim cuts Olema Pharmaceuticals stock price target on trial timing By Investing.com - Investing.com Canada
TradingKey - TradingKey
Olema Pharmaceuticals Q1 Net Loss Widens - Moomoo
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
Olema Oncology (OLMA) Focuses on Advancing Breast Cancer Treatme - GuruFocus
How to Value Olema Pharmaceuticals (OLMA) After Q1 2026 Earnings - GuruFocus
Olema Oncology Announces Q1 2026 Financial Results and Upcoming Phase 3 Breast Cancer Trial Data - Minichart
Olema Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Olema Oncology Announces First Quarter 2026 Financial and Operating Results on May 12 - geneonline.com
Olema Pharmaceuticals Ended 1Q With $505.3M Cash, Equivalents, Marketable Securities >OLMA - Moomoo
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q1 Net Loss $0.52 a Share, vs. FactSet Est of $0.52 Loss - marketscreener.com
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q1 Net Loss $0.52 a Share, Vs. FactSet Est of $0.52 Loss - Moomoo
Olema Pharmaceuticals, Inc. Q1 2026: Net income $(53.1)M, EPS $(0.52) — 10-Q Summary - TradingView
Olema Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Olema Pharmaceuticals (NASDAQ: OLMA) widens Q1 loss but ends quarter with $505M cash - Stock Titan
Olema Oncology Reports First Quarter 2026 Financial and Operating Results - The Manila Times
Olema Oncology (NASDAQ: OLMA) boosts trial spending ahead of key 2026 data - Stock Titan
Press Release: Olema Oncology Reports First Quarter 2026 Financial and Operating Results - Moomoo
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):